Glomerulosclerosis is a severe complication of many immunologically mediated kidney diseases, eventually resulting in loss of renal function. In chronic graft-versus-host disease (GvHD) in mice, a model for human lupus nephritis, the end-stage sclerotic lesions were previously shown to contain large amounts of fibronectin (FN). This study investigated a domain-specific accumulation process of circulating plasma FN (pFN) in sclerotic lesions.
Introduction
Accumulation of extracellular matrix (ECM) molecules in the glomerulus leads to the development of glomerulosclerosis, which is a prominent feature of many immunologically mediated renal diseases. Glomerulosclerosis, together with tubulointerstitial fibrosis, causes FN is involved in the regulation of cell adhesion, differentiation, migration, and proliferation.
This multifunctional protein consists of a dimer of two disulfide-bonded subunits, each with a molecular weight of approximately 220 kD, that contain binding sites for heparin, collagen, DNA, integrins, and FN itself (2, 3) . In the normal kidney FN is located in the mesangium, the glomerular basement membrane (GBM), Bowman's capsule and the tubular basement membrane (TBM) (4) . FN has a crucial role in the organization of ECM components, and is considered to play a key part in the pathogenesis of some glomerulonephritides, where the molecule is present in increased amounts in the expanded mesangium (5, 6) .
Chronic Graft-versus-Host disease (GvHD) in mice is an experimental model for human systemic lupus erythematosus (SLE), in which a transfer of donor lymphocytes into F1-hybrid recipients causes uncontrolled B-cell activation with production of autoantibodies (7) . This results in an immune complex glomerulonephritis, resembling human lupus nephritis (8) . Both in the GvHD model and in human renal diseases, the end-stage glomerulosclerotic lesions consist mainly of FN, which accumulates as a result of specific trapping of pFN from the circulation rather than through de novo synthesis (9) . The mechanism by which the specific accumulation of pFN in the sclerotic lesions takes place is still unknown. FN accumulation may result from its involvement in the blood coagulation system, or via direct binding of pFN to cells or other ECM components in the damaged glomerulus.
Because the accumulation of FN in the end-stage glomerulosclerotic lesions may be the result of an activation of the coagulation cascade, we studied the effect of heparin on the glomerular accumulation of FITC-labeled pFN in the GvHD model. Heparin is a sulfated glycosaminoglycan, closely related to heparan sulfate, with a long history in the treatment of patients with thrombotic diseases. Many ECM components, such as fibronectin, laminin, thrombospondin and different types of collagen, can bind to heparin. In addition to its anticoagulant function, heparin has an impact on interactions that involve matrix organization, cell adhesion, proliferation, and cytokine action (reviewed by (10) ). With regard to the kidney, heparin was shown to have an anti-proliferative effect on cultured vascular smooth muscle cells, epithelial cells, and mesangial cells (11) (12) (13) (14) . In several models, e.g. renal ablation, MRL/ lpr mice, puromycine aminonucleoside-induced nephrotic syndrome, and anti-Thy 1.1 nephritis in the rat, administration of heparin diminishes proteinuria and hypertension, and decelerates the progression of renal insufficiency and glomerulosclerosis in vivo (15) (16) (17) (18) (19) .
Our results show that both heparin and N-desulfated heparin can block accumulation of injected pFN-FITC and specific Cathepsin-induced FN fragments in glomerulosclerotic lesions.
These results provide evidence for a domain-specific accumulation process in the accumulation of circulating FN in sclerotic lesions.
Materials and methods

Animals
DBA/2 and C57BL/10*DBA/2 F1 hybrid mice were purchased from Harlan BV (Horst, The Netherlands). Female DBA/2 mice aged 7 to 8 weeks served as donors of lymphocytes in the induction of GvHD. Eight to 10 week-old female F1 hybrids served as recipients of lymphocytes.
GvHD was induced in 61 experimental F1 hybrid mice. Eleven age-and sex-matched normal F1 hybrid mice (NF1) were used as controls. The numbers of animals used for each experiment are detailed in the results section.
Induction of disease
GvHD was induced in F1 hybrid mice as described previously (20) . In brief, single cell suspensions were prepared from DBA/2 spleens, lymph nodes, and thymi in Hanks' balanced salt solution (HBSS). The total number of cells and the proportion of vital cells were determined by Trypan blue staining. The suspensions were mixed, and injected intravenously in F1 recipients on days 0, 3, 7, and 10. Each dose of 25*10 6 viable DBA/2 cells in 0.25 ml HBSS was composed of approximately 60% spleen cells, 30% thymocytes, and 10% lymph-node cells.
Accumulation experiments
All accumulation experiments were performed 10-12 weeks after the induction of GvHD, since specific trapping of pFN in the glomerulosclerotic lesions has been shown to occur at this 
Follow-up of F1 mice
The urine albumin content of the GvHD F1 mice was determined at two-weekly intervals, 
Preparation of non-anti-coagulant heparin
Heparin (Organon Teknika Nederland BV, Boxtel, The Netherlands) was converted into Ndesulfated non-anti-coagulant heparin according to the procedure of Inoue and Nagasawa (22) . In brief, sodium-heparin salt dissolved in 0.1 M HCl was converted into a pyridin-heparin salt on a DOWEX column (Pharmacia, Uppsala, Sweden). Desulfation was performed by using dimethyl sulfoxide/5% methanol. Activated partial thromboplastin time (aPTT) was performed according to the manufacturers protocol (Boehringer, Mannheim, Germany). N-desulfated nonanti-coagulant heparin had no effect on the clotting time. In an ELISA under isotonic conditions, non-anti-coagulant heparin and anti-coagulant heparin were found to have comparable binding capacities to pFN (unpublished results).
Statistical analysis
Results are presented as means ± SD where indicated, and were analyzed using the Chi-square test. P ≤ 0.05 was considered statistically significant.
Results
Clinical course of GvHD
Four weeks after the induction of GvHD, mice developed abnormal proteinuria. Albuminuria reached the highest levels at week 12 (results not shown). At this timepoint the majority of the animals developed ascites and edema. Light-microscopy of kidney sections of GvHD mice showed a lupus type of nephritis, complicated by focal and segmental glomerulosclerosis starting 10 weeks after the induction of the disease (Fig. 1) , confirming earlier results (20) . Repeated N-terminal sequencing of the low-affinity fraction suggests that the N-terminus of the 120 kD fragment was located near the low-affinity heparin-binding domain, but we were not able to find one unequivocal starting point for the sequence. The 100 kD proteins in both samples were not identical to each other, but the 100 kD protein fragment in the low-affinity fraction shared sequence homology with the 120 kD pFN fragment, while the 60 kD pFN fragment shared sequence homology with the 100 kD protein fragment in the high-affinity fraction. Figure 3 shows a proposed schematic drawing of the FN protein sequence indicating the proposed locations of the FN fragments. There was no statistically significant difference between the accumulation of pFN-FITC pre- Figure B is a PAS staining of a mouse glomerulus 10 weeks after the induction of GvHD, showing extensive glomerulosclerosis. The integrin α5 chain is expressed in minimal amounts in a glomerulus of a NF1 mouse (C). Increased expression of the integrin α5 chain is visible in the periphery of the glomerulosclerotic lesion 8 weeks after the induction of GvHD (D). The integrin α4 chain was expressed in trace amounts in glomeruli of NF1 mice (E). The expression of the integrin α4 chain did not alter during GvHD (Fig. F, GvHD Polyacrylamide gel electrophoresis under reducing conditions of plasma-fibronectin isolated from normal mouse plasma using a gelatin-Sepharose 4B affinity column. Lane A represents molecular weight markers. Lane B contains total FN with an apparent MW of 220 kD. Lane C shows Cathepsin D induced fragments of total FN. There is no 220 kD FN band left after enzymatic digestion. Affinity purification of the fragment-mixture, on a heparin-Sepharose 4B column, resulted in a low-affinity fraction containing a specific 120 kD FN fragment (Lane D) and a high-affinity fraction containing a specific 60 kD FN fragment (Lane E). The low-affinity fraction (120kD) was completely depleted of the 60 kD band, while the high-affinity fraction (60 kD) did not contain any 120 kD FN fragments. Additional pFN fragments with an apparent MW of about 100 kD are present in both fractions. 
Both heparin and N-desulfated non-anti-coagulant heparin prevent binding of pFN to glomerulosclerotic lesions
Discussion
Circulating pFN, which is produced by the liver, accumulates in glomerulosclerotic lesions at a late stage in GvHD (9) . This dimeric glycoprotein is known to play a role in a variety of cellular processes, immune complex clearance, and wound healing. Several domains within the FN molecule may be involved in the specific binding to the sclerotic lesion. The actual accumulation of pFN may result from 1) direct binding to other ECM components in the damaged glomerulus, 2) direct binding to beta-1 integrins on cell surfaces, 3) involvement of the coagulation system, or 4) binding to itself by polymerization via self-assembly sites into insoluble fibrils, or from a combination of these mechanisms. Schematic drawing of the total FN protein sequence (top) and the pFN protein sequece (bottom), with the proposed locations of the FN fragments involved in the accumulation of FN in glomerulosclerotic lesions. Indicated are the EIIIA, EIIIB and V regions, which can be included in or excluded from the protein by alternative splicing of the FN pre-mRNA. Rectangles represent homologous type I repeats, circles represent homologout type II repeats, and squares represent homologous type III repeats. The protein sequence of the high-affinity fraction starts at residue 1704 (homology repeat III 11 ), just before the highaffinity heparin-binding domain (Hep II). The N-terminus of the low-affinity fraction is suggested to be located near the low-affinity heparin-binding domain (Hep I, homology repeat I 1-5 ).
Firstly, FN can bind to other ECM molecules, such as collagen and laminin, that are produced and deposited in the kidney to maintain a stable matrix. Alterations in the ECM turnover that may contribute to the accumulation of FN have been described to precede the development of glomerulosclerosis in the GvHD model (25) . Secondly, stabilization of the tissue is also obtained (Table 1 ). This suggests the involvement of either one of the heparin binding sites of FN in its glomerular accumulation. To investigate whether FN binds to the glomerulus via its high-or low-affinity heparin-binding domain, FN was digested with Cathepsin D, after which the fragments were separated on a heparin affinity column. Thus, two batches of FN fragments were obtained with either low or high affinity for heparin, respectively. The 100 kD fragments present in both fractions appeared to have no functional effect during the accumulation experiments. Further molecular dissection of these fragments will be required to obtain conclusive evidence for their non-involvement.
In contrast to our expectation, the fraction with FN fragments containing the high-affinity heparin II binding domain did not accumulate in the sclerotic glomeruli, whereas the FN fraction containing the low-affinity binding site for heparin (heparin I binding domain) did. The accumulation of the latter fraction could be inhibited by pre-incubation with heparin ( Table I ), suggesting that FN does not bind to the glomerulus via its high-affinity heparin-binding region, but probably via its low-affinity heparin-binding domain, or via a site nearby. In the latter case, we hypothesize that the protective effect of heparin treatment could result from steric hindrance of the specific binding site, or heparin might act via other unknown mechanisms. Therefore, we conclude that i) the protective effect of heparin is independent of its anti- (35) . It has been suggested that this self-assembly site of FN is protected from spontaneous polymerization by keeping it cryptic, and that it is only unmasked in response to either physiological stimuli, or to tissue repair reactions. Based on these observations and ours, we hypothesize that self-assembly of soluble pFN after binding to FN molecules already present in the glomerular ECM contributes to the observed accumulation of FN during the development of glomerulosclerosis in a late stage of GvHD.
In conclusion, our results provide evidence for progressive accumulation of FN in glomerulosclerotic lesions in our model via its low-affinity heparin binding site or a site nearby.
This may involve a self-assembly process involving the first five type I (I1-5) repeats, or the first type III (III1) repeat, or both. However, the extent to which this self-assembly process is preceded by initial binding of FN to either ECM or beta 1 integrins requires further investigation.
